The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.
 
Kyle M. Rose
Employment - Urogen pharma
 
Prithvi Murthy
No Relationships to Disclose
 
Billie Gould
No Relationships to Disclose
 
Heather L. Huelster
No Relationships to Disclose
 
Facundo Davaro
No Relationships to Disclose
 
Lucia P. Camperlengo
No Relationships to Disclose
 
Pan Du
Employment - Predicine
Leadership - Predicine
Stock and Other Ownership Interests - Predicine
 
Shidong Jia
No Relationships to Disclose
 
Aram Vosoughi
No Relationships to Disclose
 
G. Daniel Grass
No Relationships to Disclose
 
Philippe E. Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN; Société Internationale d’Urologie Journal
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Scott Michael Gilbert
No Relationships to Disclose
 
Wade J. Sexton
Consulting or Advisory Role - pacific edge; Urogen pharma
 
Roger Li
Stock and Other Ownership Interests - crispr therapeutics; Guardant Health
Consulting or Advisory Role - Arquer Diagnostics; Bristol-Myers Squibb; FerGene; Ferring
Research Funding - CG Oncology
Expert Testimony - CG Oncology
Other Relationship - Predicine